澳大利亚昆士兰州大环内酯耐药性生殖支原体水平较高。
High levels of macrolide-resistant Mycoplasma genitalium in Queensland, Australia.
作者信息
Trembizki Ella, Buckley Cameron, Bletchly Cheryl, Nimmo Graeme R, Whiley David M
机构信息
UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland 4029, Australia.
Pathology Queensland Central Laboratory, Brisbane, Queensland 4029, Australia.
出版信息
J Med Microbiol. 2017 Oct;66(10):1451-1453. doi: 10.1099/jmm.0.000584. Epub 2017 Sep 12.
The macrolide azithromycin is recommended for treatment of Mycoplasma genitalium infection; however, M. genitalium strains possessing macrolide resistance-mediating mutations (MRMMs) are increasingly being reported. Here, we used the SpeeDx ResistancePlus MG kit, which provides simultaneous detection of M. genitalium and MRMMs, to assess MRMM carriage among M. genitalium infections in Queensland, Australia. Performance characteristics of the ResistancePlus MG kit for M. genitalium detection were compared to in-house PCR. Available M. genitalium PCR-positive (n=67) and negative (n=281) samples from the years 2011 to 2017 were tested using the SpeeDx ResistancePlus MG kit. In total, 63.6 % M. genitalium-positive samples were indicated to harbour MRMMs. The ResistancePlus MG method provided sensitivity and specificity of 97 and 99.6 % respectively compared to in-house PCR for M. genitalium detection. Such high levels of macrolide-resistant M. genitalium raise further concerns over future use of azithromycin for treatment of M. genitalium infection.
大环内酯类药物阿奇霉素被推荐用于治疗生殖支原体感染；然而，越来越多的报道称存在携带介导大环内酯耐药性突变（MRMMs）的生殖支原体菌株。在此，我们使用SpeeDx ResistancePlus MG试剂盒（该试剂盒可同时检测生殖支原体和MRMMs）来评估澳大利亚昆士兰州生殖支原体感染中MRMM的携带情况。将ResistancePlus MG试剂盒检测生殖支原体的性能特征与内部聚合酶链反应（PCR）进行了比较。使用SpeeDx ResistancePlus MG试剂盒对2011年至2017年期间可获得的生殖支原体PCR阳性（n = 67）和阴性（n = 281）样本进行检测。总体而言，63.6%的生殖支原体阳性样本显示携带MRMMs。与用于检测生殖支原体的内部PCR相比，ResistancePlus MG方法的灵敏度和特异性分别为97%和99.6%。如此高比例的大环内酯耐药性生殖支原体进一步引发了人们对未来使用阿奇霉素治疗生殖支原体感染的担忧。
Zotero 插件